AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8889904
Drug: Dirithromycin 500
RxNorm normalized name: Dirithromycin
DrugBank: Dirithromycin (DB00954)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dirithromycin 500 mg orally once daily
Trial: 8889904
Drug: Erythromycin base
RxNorm normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin base 250 mg orally four times daily
Trial: 1478125
Drug: Captopril (4-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (4-week treatment)
Trial: 1478125
Drug: Captopril (3-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (3-day treatment)
Trial: 6362830
Drug: High-dose DTIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose DTIC plus actinomycin D
Trial: 6362830
Drug: High-dose DTIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose DTIC plus actinomycin D (with prior disease-free interval > 6 months)
Trial: 6362830
Drug: Immunotherapy limb
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy limb (BHD plus levamisole)
Trial: 29469022
Drug: GNB3 non-risk
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GNB3 non-risk CC homozygotes
Trial: 21968714
Drug: Morphine bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine bolus
Trial: 16198334
Drug: Ozone therapy
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone therapy (local and rectal insufflation of the gas)
Trial: 16198334
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy (topical and systemic)
Trial: 12195347
Drug: HAART plus
RxNorm normalized name: Tri-Heart Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAART plus low-dose prolonged intermittent interleukin (IL)-2 (n=12)
Trial: 10363339
Drug: Statistical model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statistical model examining treatment efficacy in randomized phase III trials with varying alpha levels and sample sizes.
Trial: 131139
Drug: Thymoxamine or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymoxamine or cromolyn sodium inhalation
Trial: 31671060
Drug: SVG-DES (Drug-Eluting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SVG-DES (Drug-Eluting Stent)
Trial: 27815344
Drug: SVG-MT (Medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SVG-MT (Medical Treatment)
Trial: 15721027
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (0.625 mg/day of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate)
Trial: 15721027
Drug: Antioxidant vitamins
RxNorm normalized name: antioxidant vitamins with minerals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant vitamins (400 IU of Vitamin E and 500 mg of Vitamin C twice daily)
Trial: 15721027
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for hormone therapy
Trial: 12893194
Drug: Amifostine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifostine (500 mg/m(2)/day days 1‐5) with Topotecan (1.25 mg/m(2)/day days 1‐5)
Trial: 12893194
Drug: Topotecan (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan (1.5 mg/m(2)/day days 1‐5)
Trial: 1752117
Drug: Bradykinin (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bradykinin (various doses)
Trial: 6279061
Drug: Topical administration
RxNorm normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration of delta 9-tetrahydrocannabinol (THC)
Trial: 25023784
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate (30 mg/day of elemental iron for 12 weeks)
Trial: 25023784
Drug: Iron bis-glycinate
RxNorm normalized name: prenatal vitamin no.86/iron bis-glycinate/folic acid 32 mg-1,000 mcg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron bis-glycinate chelate (30 mg/day of elemental iron for 12 weeks)
Trial: 22180580
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine replacement therapy (15 mg for 8 weeks)
Trial: 18665187
Drug: Quality-of-life diagnosis
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quality-of-life diagnosis and therapy (QoL system) implemented for breast cancer patients.
Trial: 17132382
Drug: treatment protocol
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment protocol based on a formalised expert opinion
Trial: 11095656
Drug: Low dialysate
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dialysate sodium concentration (L-Na(D))
Trial: 29411722
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg gabapentin tablet (Group G, n = 50)
Trial: 29411722
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet (Group P, n = 50)
Trial: 23262451
Drug: Inhaled MgSO(4)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled MgSO(4)
Trial: 23262451
Drug: β(2‐)agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β(2‐)agonist
Trial: 23262451
Drug: Inhaled MgSO(4)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled MgSO(4) + β(2‐)agonist
Trial: 8572664
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of deprenyl and/or 2,000 mg of tocopherol/day
Trial: 6261607
Drug: 50% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% glucose (0.5 g/kg/h) and insulin (250 U/1,000 cc) with additional insulin up to 200 U/h, maximum 800 U/10 h; 500 ml 10% crystalline amino acid solution on the 1st postoperative day.
Trial: 6261607
Drug: Ringer lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer lactate as postoperative infusion (RL-group).
Trial: 31420398
Drug: High-Intensity Treatment
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Intensity Treatment (HIT) - behaviour therapy, coaching and pharmacological advice
Trial: 25077420
Drug: 20-μg rLP2086
RxNorm normalized name: hylan G-F 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-μg rLP2086 dose
Trial: 25077420
Drug: 60-μg rLP2086
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60-μg rLP2086 dose
Trial: 17848425
Drug: ISIS 301012
RxNorm normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISIS 301012 50-400 mg administered weekly via subcutaneous injection for 4 weeks
Trial: 15250199
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of shenmai and compound danshen injection (SM‐DS) before and after PCI
Trial: 12583341
Drug: Usual western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual western medicine (Control)
Trial: 7847099
Drug: Flutamide (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide (750 mg orally daily)
Trial: 1255259
Drug: Squibb Iodotope
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Squibb Iodotope Diagnostic capsules
Trial: 1255259
Drug: Squibb Iodotope
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Squibb Iodotope Oral liquid
Trial: 1255259
Drug: Iodotope Oral
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodotope Oral liquid
Trial: 31434076
Drug: Bortezomib and
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib and Vorinostat (BV) therapy post-ASCT for 12 cycles (28-day cycles)
Trial: 31434076
Drug: Bortezomib and
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib and Vorinostat (BV) therapy post-ASCT
Trial: 28515056
Drug: Movement control
RxNorm normalized name: JOINT MOVEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Movement control exercise programme (completed three or more weekly sessions)
Trial: 30099268
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg/kg) infusion over 40 min
Trial: 21807250
Drug: Tiotropium (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium (5 μg daily)
Trial: 16452355
Drug: Hydrocortisone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (1 mg/kg every 8 hours for 5 days)
Trial: 11375843
Drug: Tramadol (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (initial dose 100 mg, can increase to 200 mg)
Trial: 11375843
Drug: Morphine (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (initial dose 5 mg for body weight ≤ 70 kg or 10 mg for body weight > 70 kg, can increase to 15 or 20 mg)
Trial: 31009097
Drug: Conservative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative therapy without ARS (Control)
Trial: 23679347
Drug: Aclidinium bromide
RxNorm normalized name: Aclidinium Bromide
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Aclidinium bromide 200 μg BID
Trial: 27215749
Drug: Aclidinium bromide
RxNorm normalized name: Aclidinium Bromide
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Aclidinium bromide 400 μg BID
Trial: 22050796
Drug: Propofol 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2.0 mg/kg at 3.3 mg/sec after normal saline pretreatment
Trial: 22050796
Drug: Propofol 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2.0 mg/kg at 3.3 mg/sec after lidocaine 0.5 mg/kg pretreatment
Trial: 22050796
Drug: Propofol 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2.0 mg/kg at 3.3 mg/sec after lidocaine 1.0 mg/kg pretreatment
Trial: 22050796
Drug: Propofol 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2.0 mg/kg at 50 mg/sec after normal saline pretreatment
Trial: 16517330
Drug: Lidocaine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1.5 mg/kg) and succinylcholine (1 mg/kg)
Trial: 16517330
Drug: Lidocaine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1.5 mg/kg) and rocuronium (1 mg/kg)
Trial: 16517330
Drug: Remifentanil (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (1 microg/kg) and succinylcholine (1 mg/kg)
Trial: 16517330
Drug: Remifentanil (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (1 microg/kg) and rocuronium (1 mg/kg)
Trial: 15052769
Drug: Percutaneous estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Percutaneous estradiol gel combined with micronized progesterone (MP) or medroxyprogesterone acetate (MPA) for 25 days per month
Trial: 9553982
Drug: Cetirizine (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (active treatment)
Trial: 8463453
Drug: 4 or
RxNorm normalized name: Dex4 Orange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 or 8 mg of sublingual buprenorphine for 21 days
Trial: 8463453
Drug: Single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of cocaine (30 mg intravenously) and morphine (10 mg intravenously)
Trial: 8463453
Drug: Daily maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily maintenance on buprenorphine
Trial: 3710059
Drug: Oleic acid
RxNorm normalized name: Oleic Acid
DrugBank: Oleic Acid (DB04224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oleic acid (4.3 g/100 ml)
Trial: 24573909
Drug: Electronic containers
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic containers for medication
Trial: 24573909
Drug: Standard packaging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard packaging for medication
Trial: 21756152
Drug: Non-ablative fractional
RxNorm normalized name: OMIDUBICEL NON-CULTURED FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-ablative fractional laser therapy (FLT) combined with intermittent daily topical bleaching (5 treatments)
Trial: 21756152
Drug: Intermittent regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent regimen of topical bleaching alone
Trial: 17373163
Drug: 3-msec alexandrite
RxNorm normalized name: Senna alexandrina seed extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-msec alexandrite laser treatment with fluences between 8 and 32 J/cm2
Trial: 17373163
Drug: Topical corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroid (TCS) cream (betamethasone dipropionate)
Trial: 17373163
Drug: 3-msec alexandrite
RxNorm normalized name: Senna alexandrina seed extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-msec alexandrite laser treatment
Trial: 16115312
Drug: Task-based, community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Task-based, community oriented teaching model in family medicine (experimental model)
Trial: 12381083
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of vitamin C
Trial: 12381083
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with a history of KD (no gamma globulin treatment)
Trial: 11067699
Drug: Community-based educational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based educational intervention for urinary incontinence (specific details on dosage and duration not available)
Trial: 8986207
Drug: Low alcohol
RxNorm normalized name: Low alcohol beer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low alcohol dose (0.48 g/kg/LBM)
Trial: 8986207
Drug: Moderate alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate alcohol dose (0.72 g/kg/LBM)
Trial: 1336131
Drug: LMWH/DHE (low-molecular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMWH/DHE (low-molecular weight heparin 1,500 U-aPTT plus dihydroergotamine 0.5 mg, once a day)
Trial: 1336131
Drug: HDHE (sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDHE (sodium heparin 5,000 U plus dihydroergotamine 0.5 mg, twice a day)
Trial: 6725660
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PUVA and UVB
Trial: 6725660
Drug: Cumulative doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative doses of PUVA and UVB
Trial: 25183657
Drug: Cholecalciferol therapy
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol therapy (50,000 IU twice weekly)
Trial: 19778914
Drug: Intranasal HC
RxNorm normalized name: Casporyn HC
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal HC gp-39 (30, 150, 300, or 600 microg, once a week)
Trial: 12414853
Drug: Oral DHEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral DHEA (50 mg/d)
Trial: 12414853
Drug: Conventional hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional hormonal replacement therapy (HRT) (20 micro g ethinyl estradiol/0.1 mg levonorgestrel)
Trial: 8565604
Drug: 0.75 percent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 percent metronidazole gel applied twice daily to the right side of the face
Trial: 8565604
Drug: 5 percent
RxNorm normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Lidocaine 5 Percent]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 percent permethrin cream applied daily to the left side of the face
Trial: 8565604
Drug: 0.75 percent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 percent metronidazole gel
Trial: 8565604
Drug: 5 percent
RxNorm normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Lidocaine 5 Percent]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 percent permethrin cream
Trial: 21482950
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplementation (0.5 mg/day)
Trial: 15644830
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg Budesonide Inhalation Suspension (BIS)
Trial: 15644830
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg Budesonide Inhalation Suspension (BIS)
Trial: 29967649
Drug: Yoga intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yoga intervention (8 weeks, twice weekly)
Trial: 14557456
Drug: Insulin sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin sensitivity measured with the euglycemic, hyperinsulinemic clamp
Trial: 14557456
Drug: Insulin secretion
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin secretion measured as the acute response to iv arginine (5 g)
Trial: 30759132
Drug: Vi-PS vaccine
RxNorm normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi-PS vaccine
Trial: 31781100
Drug: Vi-TT vaccine
RxNorm normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi-TT vaccine
Trial: 29722285
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at 0.5 µg/kg/minute (Group R 0.5)
Trial: 29722285
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at 1.0 µg/kg/minute (Group R 1.0)
Trial: 29722285
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (Group S)
Trial: 27454267
Drug: Optimized conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized conventional treatment
Trial: 22801581
Drug: Remifentanil 1
RxNorm normalized name: remifentanil 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 1 μg kg(‐1)
Trial: 22801581
Drug: Remifentanil 2
RxNorm normalized name: remifentanil 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 2 μg kg(‐1)
Trial: 22801581
Drug: Remifentanil 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 3 μg kg(‐1)
Trial: 20934602
Drug: Preexercise supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preexercise supplement (Game Time; containing caffeine, creatine, and amino acids)
Trial: 20934602
Drug: Preexercise supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preexercise supplement (Game Time)
Trial: 8549030
Drug: Netivudine 400
RxNorm normalized name: Netivudine
DrugBank: Netivudine (DB12606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netivudine 400 mg
Trial: 8549030
Drug: Netivudine 800
RxNorm normalized name: Netivudine
DrugBank: Netivudine (DB12606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netivudine 800 mg
Trial: 28270164
Drug: pegcantratinib (TRK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pegcantratinib (TRK inhibitor) applied topically for 12 weeks
Trial: 28270164
Drug: pegcantratinib (TRK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pegcantratinib (TRK inhibitor) applied topically for 4 weeks
Trial: 28270164
Drug: pegcantratinib (TRK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pegcantratinib (TRK inhibitor) and placebo
Trial: 23806846
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (GnRHa; 0.2 mg triptorelin) and standard LPS
Trial: 23806846
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (0.2 mg triptorelin) and standard LPS
Trial: 23806846
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (0.2 mg triptorelin) without LPS
Trial: 16781361
Drug: eptifibatide/reduced-dose unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eptifibatide/reduced-dose unfractionated heparin
Trial: 16781361
Drug: eptifibatide/reduced-dose enoxaparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eptifibatide/reduced-dose enoxaparin
Trial: 10634368
Drug: Spironolactone, flutamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone, flutamide, or finasteride (active drugs)
Trial: 9198827
Drug: Nicergoline (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicergoline (8 mg i.v. for 5 days, then 30 mg oral for 25 days)
Trial: 9198827
Drug: Pentoxifylline (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (1200 mg i.v. for 5 days, then 800 mg oral for 25 days)
Trial: 8497681
Drug: 200 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 micrograms salbutamol inhaled 10 min before sBPT (treatment A)
Trial: 8497681
Drug: 200 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 micrograms salbutamol inhaled 2 h before sBPT (treatment B)